Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 10/03/2022

    Innovation Day Upper Rhine provides cross-border knowledge transfer

    Inspiration, innovation, networking are the name of the game on April 12, 2022, when the trinational event “Innovation Day Upper Rhine” (IDUR) takes place at the Palais Universitaire on the University of Strasbourg campus. Twelve universities in the Upper Rhine region, including the University of Freiburg and 100 partner companies of the EU funded project “Knowledge Transfer Upper Rhine” (KTUR), invite to a day of exchange and meeting.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovation-day-upper-rhine-provides-cross-border-knowledge-transfer
  • Press release - 02/03/2022

    HPV vaccination: Numerous studies provide impressive proof of effectiveness against cervical cancer

    More and more data from various European countries prove: Vaccination against human papillomavirus not only prevents precancerous lesions, but also reliably protects against cervical cancer. On the occasion of the International HPV Awareness Day on March 4, Nobel laureate Harald zur Hausen hopes that many more parents will recognize this unique opportunity to protect their children from preventable cancers by vaccinating against HPV.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hpv-vaccination-numerous-studies-provide-impressive-proof-effectiveness-against-cervical-cancer
  • Press release - 19/10/2021

    Gips Schüle Research Award for three scientists from the University of Stuttgart

    Prof. Dr. Harald Gießen from the Institute of Physics (4) as well as Prof. Dr. Alois Herkommer and Dr. Simon Thiele from the Institute of Applied Optics at the University of Stuttgart received the Gips Schüle Research Award 2021 on October 19, 2021. The researchers were awarded the prize, which is valued at EUR 50,000.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gips-schuele-research-award-three-scientists-university-stuttgart
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpg

    Vaccines – a beacon of hope in the fight against pandemics

    Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology. The development of much-needed vaccines against many other…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Press release - 07/01/2021

    CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV

    Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-bayer-join-forces-covid-19-vaccine-candidate-cvncov
  • Development of the genomDE genome database - 04/12/2020 national-cancer-institute-to8o0bqOA6Q-unsplash.jpg

    Whole genome sequencing for diagnosing rare diseases

    Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…

    https://www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases
  • Press release - 16/11/2020

    European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), reports the European Commission’s announcement that tomorrow it will authorize an Advanced Purchase Agreement for CureVac´s mRNA-based COVID-19 vaccine candidate, CVnCoV.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/european-commission-announces-tomorrow-it-will-authorize-agreement-curevac-supply-405-million-doses-mrna-based-covid-19-vaccine
  • Press release - 20/10/2020

    EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

    The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
  • Press release - 15/09/2020

    ELLIS inaugurates 30 research units at leading institutions across Europe

    At a virtual event on Tuesday, the European Laboratory for Learning and Intelligent Systems presented the broad scope of research its units will cover in the field of modern AI.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ellis-offizieller-start-der-30-forschungseinheiten-fuehrenden-institutionen-ganz-europa
  • Stem cell therapy for regenerating intervertebral discs - 16/07/2020 800_Wisi_Focus_Web.jpg

    Ulm’s simulator has Europe’s back

    Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
  • Press release - 27/04/2020

    EIT Health pledges €6m funding to accelerate COVID-19 solutions

    EIT Health has announced over €6m of funding in the fight against COVID-19. The funding will be dedicated to 14 specially selected health innovation projects across Europe which will focus on immediate and impactful solutions that can be found to arm health services with better tools in navigating the pandemic.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eit-health-pledges-eur6m-funding-accelerate-covid-19-solutions
  • Press release - 24/03/2020

    State aid: Commission approves €300 million Luxembourg scheme to support companies affected by coronavirus outbreak

    The European Commission has found Luxembourg's €300 million scheme to support companies affected by the coronavirus outbreak to be in line with EU State aid rules. The scheme was approved under the State aid Temporary Framework to support the economy in the context of the COVID-19 outbreak adopted by the Commission on 19 March 2020.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/state-aid-commission-approves-eur300-million-luxembourg-scheme-support-companies-affected-coronavirus-outbreak
  • Press release - 23/03/2020

    COVID-19: Commission launches European team of scientific experts to strengthen EU coordination and medical response

    Today, the European Commission launched an advisory panel on COVID-19 composed of epidemiologists and virologists from different Member States to formulate EU guidelines on science-based and coordinated risk management measures.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/covid-19-kommission-setzt-europaeisches-team-wissenschaftlicher-experten-ein-um-die-koordinierung-auf-eu-ebene-und-die-medizinis
  • Press release - 28/01/2019 21359_de.jpg

    5,5 millions for project on smart matrices for knee cartilage repair

    A research project in cartilage regeneration, in which the Institute of Orthopaedic Research and Biomechanics at Ulm University participates together with partners from eight european countries, was recently financed by the European Commission with 5.5 million Euro. Named RESTORE, the project aims to create 3D matrices incorporating smart nanomaterials to repair knee cartilage lesions thereby reducing or delaying the onset of osteoarthritis,…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/55-millions-for-project-on-smart-matrices-for-knee-cartilage-repair
  • Press release - 29/11/2018

    Hattrick in Freiburg

    Three researchers at the MPI for Immunobiology and Epigenetics receive millions in funding from the European Research Council. Dominic Grün, Nicola Iovino and Ritwick Sawarkar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg will each be awareded one of the prestigious Consolidator Grants of the European Research Council. This means that 6 million euros in funding will go to fundamental research in Freiburg over the next…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hattrick-in-freiburg
  • Article - 29/10/2018 Bernhard Hirt, stehend vor einem anatomischen Modell eines Menschen, hält drei Glaskolben in den Händen.

    Aminolipine: formaldehyde-free substitute for preserving biological tissues

    For almost 125 years, undertakers as well as physicians in the fields of anatomy and pathology have used formaldehyde to preserve biological tissue and whole cadavers. Yet, formaldehyde is highly toxic and linked to cancer. A team led by Prof. Dr. Bernhard Hirt from the Institute of Clinical Anatomy and Cell Analysis at the University Hospital in Tübingen has developed a formaldehyde-free replacement substance.

    https://www.gesundheitsindustrie-bw.de/en/article/news/aminolipine-formaldehyde-free-substitute-for-preserving-biological-tissues
  • Article - 15/09/2017 Teaser_ZIKA_Virus_Jarasch.jpg

    Zika virus infections and their consequences

    Infections caused by mosquito-borne Zika viruses during pregnancy can lead to severe brain defects in babies. The European Union has provided funding of around ten million euros for an international research programme on Zika virus infections in which the University Hospital of Heidelberg plays a key role.

    https://www.gesundheitsindustrie-bw.de/en/article/news/zika-virus-infections-and-their-consequences
  • Article - 26/04/2017 Schematic representation of a mechanism leading to the fragmentation of amyloid fibrils.

    Chaperones disassemble Parkinson’s disease-specific amyloid fibrils

    Amyloid fibrils consisting of clumped α-synuclein protein are characteristic of Parkinson's disease. Chaperones, which ensure the correct folding of newly synthesised polypeptides, can inhibit α-synuclein aggregation and, as a consequence, prevent fibrils from forming. Researchers from Heidelberg have shown that a specific combination of human molecular chaperones is able to disassemble fibrils and transform them into non-toxic α-synuclein…

    https://www.gesundheitsindustrie-bw.de/en/article/news/chaperones-disassemble-parkinsons-disease-specific-amyloid-fibrils
  • Press release - 05/04/2017

    New EU rules on medical devices to enhance patient safety and modernise public health

    The Commission welcomes the adoption of its proposal for two Regulations on medical devices which establish a modernised and more robust EU legislative framework to ensure better protection of public health and patient safety.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-eu-rules-on-medical-devices-to-enhance-patient-safety-and-modernise-public-health
  • Prenatal diagnosis - 23/03/2017 A transparent plastic disk and a microscope slide that is held with a pair of tweezers.

    Microdroplets for safe and rapid prenatal diagnoses

    Although the methods used to carry out amniocentesis are quite sophisticated, there is still a 0.5 percent risk of miscarriage following the intervention. Therefore, an EU-funded project called AngeLab is developing a rapid test that only requires a blood sample of the mother rather than amniotic fluid. The test yields information on the genetic health of the foetus within only a few hours. As part of the project, researchers from the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/microdroplets-for-safe-and-rapid-prenatal-diagnoses
  • Article - 22/02/2017 Woman wearing a lab coat in front of a laboratory device. The photo shows the back of the woman.

    MammaScreen – blood test for early detection of breast cancer

    The MammaScreen team from the University of Heidelberg Women’s Hospital has developed a blood test for diagnosing breast cancer. This new test can detect breast cancer at a very early stage. It works on women of all ages with tumours of any type and size.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mammascreen-blood-test-for-early-detection-of-breast-cancer
  • High-tech - 20/10/2016 Man standing in front of a robot.

    Industry 4.0 in the medical technology and pharmaceutical industry sectors

    The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/industry-40-in-the-medical-technology-and-pharmaceutical-industry-sectors
  • Press release - 12/02/2016

    ERC Consolidator Grants: € 585 million for 302 top researchers in Europe

    The European Research Council (ERC) has announced today the 302 winners of its 2015 Consolidator Grant competition. These excellent mid-career scientists are awarded a total of €585 million, as part of the European Union Research and Innovation programme Horizon 2020. With grants worth up to €2 million each, they will be able to consolidate their research teams and to develop their innovative ideas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-consolidator-grants-585-million-for-302-top-researchers-in-europe
  • Article - 02/02/2016 Innovation.jpg

    EU consortium to speed up innovations in the healthcare sector

    EIT Health is a large-scale European project launched in December 2014 that aims to help people in Europe to live a healthier life and stay active as they grow older. The consortium brings together 140 leading companies and institutions from 14 European countries and has a total budget of two billion euros. It is one of the largest networks worldwide in the healthcare sector.

    https://www.gesundheitsindustrie-bw.de/en/article/news/eu-consortium-to-speed-up-innovations-in-the-healthcare-sector
  • Article - 04/08/2014 Photo showing an electron microscope image of adeno-associated viruses (AAV).

    Europe’s first gene therapy

    Scientists from the National Center for Tumour Diseases (NCT) have shown that adeno-associated viruses (AAV) do not pose a cancer risk. This conclusion is based on the analysis of several million patient cells treated with AAV and the finding that the viruses do not integrate into the patient genome. AAV is the first-ever gene therapy for clinical use in the Western world. AAV vectors could also potentially be used as prototypes for the treatment…

    https://www.gesundheitsindustrie-bw.de/en/article/news/europe-s-first-gene-therapy

Page 1 / 4

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search